
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you open and fund a new account within 30 days
- Access to a financial planner
TC BioPharm Holdings is a biotechnology business based in the US. TC BioPharm Holdings shares (TCBP) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.50 – the same closing value as a week prior. TC BioPharm Holdings employs 41 staff and has a trailing 12-month revenue of around $2.9 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Latest market close | $0.50 |
---|---|
52-week range | $0.50 - $523.20 |
50-day moving average | $3.86 |
200-day moving average | $8.94 |
Wall St. target price | $140.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-192.95 |
Historical closes compared with the close of $0.5 from 2025-03-21
1 week (2025-03-22) | N/A |
---|---|
1 month (2025-02-28) | -74.36% |
3 months (2025-01-02) | -17.49% |
6 months (2024-10-02) | -91.55% |
1 year (2024-04-02) | -60.63% |
---|---|
2 years (2023-03-31) | -99.99% |
3 years (2022-04-01) | 217600.0033 |
5 years (2020-03-29) | N/A |
Revenue TTM | $2.9 million |
---|---|
Gross profit TTM | $3.8 million |
Return on assets TTM | -108.92% |
Return on equity TTM | -1217.48% |
Profit margin | 0% |
Book value | $3.38 |
Market Capitalization | $360,373 |
TTM: trailing 12 months
We're not expecting TC BioPharm Holdings to pay a dividend over the next 12 months.
You may also wish to consider:
TC BioPharm Holdings's shares were split on a 1:10 basis on 4 August 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TC BioPharm Holdings shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for TC BioPharm Holdings shares which in turn could have impacted TC BioPharm Holdings's share price.
Over the last 12 months, TC BioPharm Holdings's shares have ranged in value from as little as $0.5 up to $523.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while TC BioPharm Holdings's is 0.249. This would suggest that TC BioPharm Holdings's shares are less volatile than average (for this exchange).
To put TC BioPharm Holdings's beta into context you can compare it against those of similar companies.
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. .
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.